Woolland steps up to steer fresh growth phase for Closed Loop Medicine
Woolland will lead CLM as it moves into a new phase focused on enabling partner-led deployment and market scale, building on the company’s proven innovation platform. Closed Loop is focused on maximising the value of its extensive intellectual property (IP) through pharmaceutical and other partnerships as well as IP licensing and integration opportunities.
CLM has developed a uniquely valuable IP portfolio specifically designed to extend branded drug lifecycles, protect market exclusivity, and create differentiated therapeutic offerings to improve patient outcomes.
With over 60 filings across 16 patent families granted in the US and globally, the company’s IP covers both platform and therapy-specific technologies, including precision dosing for GLP-1 therapies, hypertension, and other major therapeutic areas.
Following a rapid response to expand its IP across GLP-1 and incretin therapies, dose optimisation protocols, and treatment algorithms, CLM believes it is uniquely positioned as metabolic health markets experience rapid growth.
CLM’s proprietary approach has demonstrated improved patient adherence rates to over 90 per cent in clinical settings through personalised titration. The company’s comprehensive regulatory strategy includes multi-region approvals spanning pharmaceutical and digital health, both UK and US clearances, with full ISO13485/ISO27001 quality management compliance.
"Our precision dosing platform has reached a breadth and maturity level that creates significant strategic value for pharmaceutical companies and health delivery companies, particularly in large markets like the US," said Woolland.
"As we enter this new phase, we're focused on identifying the right partners who can fully leverage our technology to transform patient outcomes at scale across multiple therapeutic areas."
Under her leadership, CLM intends to build on its foundation of cross-functional expertise in pharmaceutical development, digital health, regulatory strategy and commercial execution. Her previous experience includes successfully launching commercial healthcare products as Chief Delivery Officer at ieso Digital Health and building a healthcare transformation business worth over £10 million p.a. as a Partner at PA Consulting.
She added: "The combined expertise of our team, and our broad IP portfolio, enables us to build products that enable clinicians to truly personalise the dosing of medication and empower patients to better understand and manage their condition.
"We see huge improvements in adherence to medication when our products are deployed, ultimately leading to better health outcomes. This capability becomes particularly valuable when integrated with larger commercial organisations seeking to enhance, extend and expand their therapeutic portfolios and digital capabilities and maximise market share.”